exhibit 10. 3 certain information identified by “ [ * * * ] ” has been excluded from the exhibit because it is both not material and is the type of information that the registrant treats as private or confidential. amendment no. 4 to market access services agreement this amendment no. 4 ( this “ amendment ” ) is entered into as of august 9, 2022 ( the “ amendment effective date ” ) by and between sunovion pharmaceuticals inc., a delaware corporation, having a principle place of business at 84 waterford drive, marlborough, ma 01752 ( “ sunovion ” ) and myovant sciences gmbh, a swiss corporation, having a principle place of business at viaduktstrasse 8, 4051 basel, switzerland ( “ myovant ” ). capitalized terms used in this amendment that are not defined in this amendment shall have the meaning set forth in the agreement ( as defined below ). recitals a. sunovion and myovant entered into that certain market access services agreement dated august 1, 2020 and amended as of december 14, 2020, january 25, 2021, march 15, 2021 and august 9, 2022 ( collectively, the “ agreement ” ) ; sunovion and myovant entered into that certain market access services agreement dated august 1, 2020 and amended as of december 14, 2020, january 25, 2021, march 15, 2021 and august 9, 2022 ( collectively, the “ b. sunovion and myovant acknowledge and agree the amendment titled “ amendment no. 1 to market access services agreement ” to the agreement entered into by and between the parties effective december 14, 2020 is the first amendment to the agreement ; sunovion and myovant acknowledge and agree the amendment titled “ amendment no. 1 to market access services agreement ” to the agreement entered into by and between the parties effective december 14, 2020 is the first amendment to the agreement ; c. sunovion and myovant acknowledge and agree the amendment titled “ amendment no. 2 to market access services agreement ” entered into by and between the parties effective january 25, 2021 is the second amendment to the agreement ; sunovion and myovant acknowledge and agree the amendment titled “ amendment no. 2 to market access services agreement ” entered into by and between the parties effective january 25, 2021 is the second amendment to the agreement ; d. sunovion and myovant acknowledge and agree the amendment titled “ amendment no.